@article{Mastellari2025,
abstract = {BACKGROUND: Lorazepam, a widely used benzodiazepine, is the first-line treatment  for catatonia. In case of resistance to Lorazepam, a trial-and-error approach is usually followed, increasing the risk of severe medical complications. To date, the mechanisms underlying non-response to Lorazepam remain unclear. The aims of this study were to determine whether network analysis can identify symptom-based predictors of response to Lorazepam and assess whether the structure of catatonic symptoms differs between responders and non-responders. METHODS: A cohort of patients with catatonia (n = 136) was recruited at a specialized clinical center. Network analyses were conducted using the Bush-Francis Catatonia Rating Scale items, to describe the structure of catatonic symptoms in responders and non-responders to Lorazepam. Symptom clusters were identified using a spinglass algorithm and centrality measures were compared between groups. Additionally, network outcome analyses were performed to identify clinical predictors of Lorazepam response. RESULTS: Three clusters of catatonic symptoms were identified, with similar structure between responders and non-responders. No significant differences were found in centrality measures. The most central symptoms were characteristics of hyperkinetic catatonia. Immobility / stupor emerged as the unique direct predictor of response to Lorazepam. CONCLUSION: The overall structure of catatonic symptoms appears stable between responders and non-responders. Hypokinetic symptoms, particularly immobility and stupor, serve as strong predictors of Lorazepam response. Given the critical need for early treatment prediction to optimize therapeutic interventions and reduce catatonia-related mortality, further research is needed to refine clinical predictors of Lorazepam response.},
author = {Mastellari, Tomas and Gauld, Christophe and Fovet, Thomas and Amad, Ali},
doi = {10.1016/j.pnpbp.2025.111435},
issn = {1878-4216 (Electronic)},
journal = {Progress in neuro-psychopharmacology & biological psychiatry},
keywords = {Adult,Catatonia,Cohort Studies,Female,Humans,Lorazepam,Male,Middle Aged,Treatment Outcome,Young Adult,diagnosis,drug therapy,therapeutic use},
language = {eng},
month = {jul},
pages = {111435},
pmid = {40619051},
title = {{Predicting the response to Lorazepam in catatonia: a network analysis approach.}},
volume = {140},
year = {2025}
}

{"_id":"WdxfNqxQfNRcLncve","bibbaseid":"mastellari-gauld-fovet-amad-predictingtheresponsetolorazepamincatatoniaanetworkanalysisapproach-2025","author_short":["Mastellari, T.","Gauld, C.","Fovet, T.","Amad, A."],"bibdata":{"bibtype":"article","type":"article","abstract":"BACKGROUND: Lorazepam, a widely used benzodiazepine, is the first-line treatment for catatonia. In case of resistance to Lorazepam, a trial-and-error approach is usually followed, increasing the risk of severe medical complications. To date, the mechanisms underlying non-response to Lorazepam remain unclear. The aims of this study were to determine whether network analysis can identify symptom-based predictors of response to Lorazepam and assess whether the structure of catatonic symptoms differs between responders and non-responders. METHODS: A cohort of patients with catatonia (n = 136) was recruited at a specialized clinical center. Network analyses were conducted using the Bush-Francis Catatonia Rating Scale items, to describe the structure of catatonic symptoms in responders and non-responders to Lorazepam. Symptom clusters were identified using a spinglass algorithm and centrality measures were compared between groups. Additionally, network outcome analyses were performed to identify clinical predictors of Lorazepam response. RESULTS: Three clusters of catatonic symptoms were identified, with similar structure between responders and non-responders. No significant differences were found in centrality measures. The most central symptoms were characteristics of hyperkinetic catatonia. Immobility / stupor emerged as the unique direct predictor of response to Lorazepam. CONCLUSION: The overall structure of catatonic symptoms appears stable between responders and non-responders. Hypokinetic symptoms, particularly immobility and stupor, serve as strong predictors of Lorazepam response. Given the critical need for early treatment prediction to optimize therapeutic interventions and reduce catatonia-related mortality, further research is needed to refine clinical predictors of Lorazepam response.","author":[{"propositions":[],"lastnames":["Mastellari"],"firstnames":["Tomas"],"suffixes":[]},{"propositions":[],"lastnames":["Gauld"],"firstnames":["Christophe"],"suffixes":[]},{"propositions":[],"lastnames":["Fovet"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Amad"],"firstnames":["Ali"],"suffixes":[]}],"doi":"10.1016/j.pnpbp.2025.111435","issn":"1878-4216 (Electronic)","journal":"Progress in neuro-psychopharmacology & biological psychiatry","keywords":"Adult,Catatonia,Cohort Studies,Female,Humans,Lorazepam,Male,Middle Aged,Treatment Outcome,Young Adult,diagnosis,drug therapy,therapeutic use","language":"eng","month":"jul","pages":"111435","pmid":"40619051","title":"Predicting the response to Lorazepam in catatonia: a network analysis approach.","volume":"140","year":"2025","bibtex":"@article{Mastellari2025,\nabstract = {BACKGROUND: Lorazepam, a widely used benzodiazepine, is the first-line treatment for catatonia. In case of resistance to Lorazepam, a trial-and-error approach is usually followed, increasing the risk of severe medical complications. To date, the mechanisms underlying non-response to Lorazepam remain unclear. The aims of this study were to determine whether network analysis can identify symptom-based predictors of response to Lorazepam and assess whether the structure of catatonic symptoms differs between responders and non-responders. METHODS: A cohort of patients with catatonia (n = 136) was recruited at a specialized clinical center. Network analyses were conducted using the Bush-Francis Catatonia Rating Scale items, to describe the structure of catatonic symptoms in responders and non-responders to Lorazepam. Symptom clusters were identified using a spinglass algorithm and centrality measures were compared between groups. Additionally, network outcome analyses were performed to identify clinical predictors of Lorazepam response. RESULTS: Three clusters of catatonic symptoms were identified, with similar structure between responders and non-responders. No significant differences were found in centrality measures. The most central symptoms were characteristics of hyperkinetic catatonia. Immobility / stupor emerged as the unique direct predictor of response to Lorazepam. CONCLUSION: The overall structure of catatonic symptoms appears stable between responders and non-responders. Hypokinetic symptoms, particularly immobility and stupor, serve as strong predictors of Lorazepam response. Given the critical need for early treatment prediction to optimize therapeutic interventions and reduce catatonia-related mortality, further research is needed to refine clinical predictors of Lorazepam response.},\nauthor = {Mastellari, Tomas and Gauld, Christophe and Fovet, Thomas and Amad, Ali},\ndoi = {10.1016/j.pnpbp.2025.111435},\nissn = {1878-4216 (Electronic)},\njournal = {Progress in neuro-psychopharmacology & biological psychiatry},\nkeywords = {Adult,Catatonia,Cohort Studies,Female,Humans,Lorazepam,Male,Middle Aged,Treatment Outcome,Young Adult,diagnosis,drug therapy,therapeutic use},\nlanguage = {eng},\nmonth = {jul},\npages = {111435},\npmid = {40619051},\ntitle = {{Predicting the response to Lorazepam in catatonia: a network analysis approach.}},\nvolume = {140},\nyear = {2025}\n}\n","author_short":["Mastellari, T.","Gauld, C.","Fovet, T.","Amad, A."],"key":"Mastellari2025","id":"Mastellari2025","bibbaseid":"mastellari-gauld-fovet-amad-predictingtheresponsetolorazepamincatatoniaanetworkanalysisapproach-2025","role":"author","urls":{},"keyword":["Adult","Catatonia","Cohort Studies","Female","Humans","Lorazepam","Male","Middle Aged","Treatment Outcome","Young Adult","diagnosis","drug therapy","therapeutic use"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://nextcloud.univ-lille.fr/index.php/s/ZN4QZ7dH9iNaNWE/download/Interactions.bib","dataSources":["ECsXQHgbAjNJDKiJ7"],"keywords":["adult","catatonia","cohort studies","female","humans","lorazepam","male","middle aged","treatment outcome","young adult","diagnosis","drug therapy","therapeutic use"],"search_terms":["predicting","response","lorazepam","catatonia","network","analysis","approach","mastellari","gauld","fovet","amad"],"title":"Predicting the response to Lorazepam in catatonia: a network analysis approach.","year":2025}